Safety is paramount in any therapeutic modality, and photobiomodulation therapy has shown no detected neuroinflammatory responses, making it particularly suitable for sensitive applications. This exceptional safety profile extends even to pediatric applications, where the developing brain requires the utmost care and protection, positioning our technology as a trusted solution for practitioners seeking effective, low-risk therapeutic interventions.

Photobiomodulation therapy with Class IV lasers demonstrates an excellent safety profile, with only mild and transient side effects reported in clinical use. The most commonly observed effects are temporary in nature and resolve quickly without intervention. Patients may occasionally experience transient headaches (rare occurrence), temporary diastolic blood pressure increase, mild irritability (uncommon), or the perception of vivid colors during treatment sessions. These mild effects are well-documented and do not require treatment cessation, making photobiomodulation therapy one of the safest therapeutic modalities available for pain management and tissue healing. The minimal side effect profile, combined with the non-invasive nature of light therapy, makes this treatment option highly tolerable for diverse patient populations across multiple clinical applications.